4.26
+0.1094(+2.64%)
Currency In USD
| Previous Close | 4.15 |
| Open | 4.13 |
| Day High | 4.31 |
| Day Low | 4.11 |
| 52-Week High | 11 |
| 52-Week Low | 3.4 |
| Volume | 347,449 |
| Average Volume | 524,833 |
| Market Cap | 75.23M |
| PE | -1.55 |
| EPS | -2.74 |
| Moving Average 50 Days | 4.24 |
| Moving Average 200 Days | 5.67 |
| Change | 0.11 |
If you invested $1000 in Unicycive Therapeutics, Inc. (UNCY) since IPO date, it would be worth $85.19 as of September 30, 2025 at a share price of $4.259. Whereas If you bought $1000 worth of Unicycive Therapeutics, Inc. (UNCY) shares 3 years ago, it would be worth $721.93 as of September 30, 2025 at a share price of $4.259.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Unicycive Therapeutics to Participate in Upcoming Investor Events in September
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shal
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
GlobeNewswire Inc.
Aug 18, 2025 11:05 AM GMT
Ensures Intellectual Property Protection Until 2040LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
GlobeNewswire Inc.
Jul 24, 2025 12:00 PM GMT
OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burdenLOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company develo